Abstract
Melatonin, as a new member of an expanding group of regulatory factors that control cell proliferation and loss, is the only known chronobiotic, hormonal regulator of neoplastic cell growth. At physiological circulating concentrations, this indoleamine is cytostatic and inhibits cancer cell proliferation in vitro via specific cell cycle effects. At pharmacological concentrations, melatonin exhibits cytotoxic activity in cancer cells. At both physiological and pharmacological concentrations, melatonin acts as a differentiating agent in some cancer cells and lowers their invasive and metastatic status through alterations in adhesion molecules and maintenance of gap junctional intercellular communication. In other cancer cell types, melatonin, either alone or in combination with other agents, induces apoptotic cell death. Biochemical and molecular mechanisms of melatonins oncostatic action may include regulation of estrogen receptor expression and transactivation, calcium / calmodulin activity, prote in kinase C activity, cytoskeletal architecture and function, intracellular redox status, melatonin receptor-mediated signal transduction cascades, and fatty acid transport and metabolism. A major mechanism mediating melatonins circadian stage-dependent tumor growth inhibitory action is the suppression of epidermal growth factor receptor (EGFR) / mitogen-activated protein kinase (MAPK) activity. This occurs via melatonin receptor-mediated blockade of tumor linoleic acid uptake and its conversion to 13-hydroxyoctadecadienoic acid (13-HODE) which normally activates EGFR / MAPK mitogenic signaling. This represents a potentially unifying model for the chronobiological inhibitory regulation of cancer growth by melatonin in the maintenance of the host / cancer balance. It also provides the first biological explanation of melatonin-induced enhancement of the efficacy and reduced toxicity of chemo- and radiotherapy in cancer patients.
Keywords: Circadian-Based Cancer Therapy, 13-hydroxyoctadecadienoic acid (13-HODE), Estrogen Response Pathway, glutathione (GSH), Chronobiological
Current Topics in Medicinal Chemistry
Title: Melatonin as a Chronobiotic / Anticancer Agent: Cellular, Biochemical, and Molecular Mechanisms of Action and their Implications for Circadian-Based Cancer Therapy
Volume: 2 Issue: 2
Author(s): David E. Blask, Leonard A. Sauer and Robert T. Dauchy
Affiliation:
Keywords: Circadian-Based Cancer Therapy, 13-hydroxyoctadecadienoic acid (13-HODE), Estrogen Response Pathway, glutathione (GSH), Chronobiological
Abstract: Melatonin, as a new member of an expanding group of regulatory factors that control cell proliferation and loss, is the only known chronobiotic, hormonal regulator of neoplastic cell growth. At physiological circulating concentrations, this indoleamine is cytostatic and inhibits cancer cell proliferation in vitro via specific cell cycle effects. At pharmacological concentrations, melatonin exhibits cytotoxic activity in cancer cells. At both physiological and pharmacological concentrations, melatonin acts as a differentiating agent in some cancer cells and lowers their invasive and metastatic status through alterations in adhesion molecules and maintenance of gap junctional intercellular communication. In other cancer cell types, melatonin, either alone or in combination with other agents, induces apoptotic cell death. Biochemical and molecular mechanisms of melatonins oncostatic action may include regulation of estrogen receptor expression and transactivation, calcium / calmodulin activity, prote in kinase C activity, cytoskeletal architecture and function, intracellular redox status, melatonin receptor-mediated signal transduction cascades, and fatty acid transport and metabolism. A major mechanism mediating melatonins circadian stage-dependent tumor growth inhibitory action is the suppression of epidermal growth factor receptor (EGFR) / mitogen-activated protein kinase (MAPK) activity. This occurs via melatonin receptor-mediated blockade of tumor linoleic acid uptake and its conversion to 13-hydroxyoctadecadienoic acid (13-HODE) which normally activates EGFR / MAPK mitogenic signaling. This represents a potentially unifying model for the chronobiological inhibitory regulation of cancer growth by melatonin in the maintenance of the host / cancer balance. It also provides the first biological explanation of melatonin-induced enhancement of the efficacy and reduced toxicity of chemo- and radiotherapy in cancer patients.
Export Options
About this article
Cite this article as:
Blask E. David, Sauer A. Leonard and Dauchy T. Robert, Melatonin as a Chronobiotic / Anticancer Agent: Cellular, Biochemical, and Molecular Mechanisms of Action and their Implications for Circadian-Based Cancer Therapy, Current Topics in Medicinal Chemistry 2002; 2 (2) . https://dx.doi.org/10.2174/1568026023394407
DOI https://dx.doi.org/10.2174/1568026023394407 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Evaluation of PROGINS Mutation in Progesterone Receptor Gene and Determination of its Frequency, Distribution Pattern and Association with Breast Cancer Susceptibility in Saudi Arabia
Endocrine, Metabolic & Immune Disorders - Drug Targets Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer
Current Radiopharmaceuticals Improving the Efficacy of Plant Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy Development of Topical Nanocarriers for Skin Cancer Treatment Using Quality by Design Approach
Current Medicinal Chemistry Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Recent Patents on Anti-Cancer Drug Discovery Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry New Perspectives for Melanoma Immunotherapy: Role of IL-12
Current Molecular Medicine Cytotoxic Constituents from Vietnamese Marine Sponge <i>Haliclona oculata (Linnaeus, 1759)</i>
Letters in Organic Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity
Current Computer-Aided Drug Design EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Current Molecular Medicine An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy
Current Pharmaceutical Biotechnology Wheel of Fortune – Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
Current Chemical Biology Targeted Nanomedicines: In the Right Route Towards Improved Therapies
Current Cancer Therapy Reviews Editorial [Hot Topic: Cancer Biomarkers Guest Editor: Robert C. Rees]
Current Cancer Therapy Reviews